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Background: Angina pectoris (Angina) is a medical condition related to myocardial ischemia. Although acupuncture
has been widely accepted as a clinical approach for angina, there is no sufficient evidence of its effectiveness against
this syndrome, and its mechanisms have not yet been well elucidated. We develop this protocol to confirm the clinical
efficacy of electro-acupuncture on stable angina pectoris by needling on acupoint Neiguan (PC6). Furthermore, we
employ high-throughput sequencing technology to investigate the gene expression profiling and determine
involvement of histone modifications in the regulation of genes after electro-acupuncture treatment.
Methods/Design: A randomized, controlled, double-blinded (assessor and patients) trial will be carried out. Sixty
participants will be randomly assigned to two acupuncture treatment groups and one control group in a 1:1:1 ratio.
Participants in acupuncture groups will receive 12 sessions of electro-acupuncture treatment across 4 weeks, followed
by a 12-week randomization period. The acupuncture groups are divided into Neiguan (PC6) on Pericardium Meridian
of Hand-jueyin or a non-acupoint. The primary clinical measure of effect is the frequency of angina attacks between
these groups for four weeks after randomization. RNAs are extracted from peripheral neutrophils collected from all
participants on day 0, day 30, and week 16, and are processed to RNA-Seq. We then investigate profiles of histone
modifications by ChIP-Seq, for H3 Lysine 4 (H3K4me) and acetylation of H3 Lysine 27 (H3K27ac), in the presence or
absence of acupuncture treatment.
Discussion: This study determines the efficacy and mechanisms of electro-acupuncture on stable angina pectoris.
We focus on effectiveness of acupuncture on alleviating symptoms of myocardial ischemia and the gene regulation
and the chromatin remodeling marks, including H3K4me1, H3K4me2, and H3K27ac, which could be key factors for
regulating gene expressions caused by electro-acupuncture treatment at Neiguan. This is the first genome-wide study
of electro-acupuncture treatment in angina patients, and will provide valuable information for future studies in the
fields of acupuncture and its underlying mechanisms.
Fourteen patients have been recruited since recruitment opened in November of 2012. This study is scheduled to end
in November of 2014.
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Stable angina is a clinical syndrome characterized by dis-
comfort in the chest, jaw, shoulder, back, or arms, typi-
cally elicited by physical exertion or emotional stress and
relieved by rest or nitroglycerin [1]. Despite the multiple
medical and interventional technologies that have been
developed to reduce myocardial ischemia, stable angina
still affects nearly 60 million people in China. And despite
the association with a worsened quality of life [2], repeated
hospitalizations, and increased healthcare costs [3], angina
often remains undertreated [4,5]. Acupuncture, the most
well-known complementary and alternative medical ap-
proach, has been applied to prevent and cure many dis-
eases such as angina [6], palpitation [7], stroke [8], and
disruption of the left cardiac function in coronary heart
disease (CHD) [9] for more than 2000 years. Recent studies
show that acupuncture treatment can improve regene-
ration capacity of local micro-vascular and collateral circu-
lation during myocardia ischemia; thereby ameliorating
ischemia symptoms [10-13]. It not only quickly relieves the
symptoms of acute angina pectoris, but also improves
nitroglycerine’s therapeutic effects [14]. A review article
has concluded that the effectiveness (between 80% to
96.2%) of acupuncture therapy is comparable to conven-
tional drug regimen [14]. In addition, many conventional
anti-angina medications react adversely with other medica-
tions that the patients may be taking for other illnesses,
whereas acupuncture therapy does not pose such an inter-
ference with the patient’s medical regimen. Clinical ex-
perience has suggested that myocardial ischemia can be
effectively treated via acupuncture at a single acupoint,
Neiguan (PC6), which is first described in Miraculous Pivot
Meridians. Neiguan (PC6) indicates a point located 2 cun
above the transverse crease of the wrist and between the
tendons of m. Palmaris longus and m. flexor radialis. And
because this point is connected to the pericardium, it can
also be used to treat precordial pain [15]. Neiguan (PC6) is
the Luo point of the pericardium meridian of hand-jueyin,
as well as one of the eight confluence acupoints.
Many have proven that needling at PC6 can protect
against myocardial ischemic injury through multiple
mechanisms, including improving angiogenesis and re-
ducing apoptosis and calcium overload [16-18]. Though
some studies have looked at the systemic alternations of
functional molecules after median nerve stimulation in
rats with myocardial ischemic injury [19], no epigenetic
research has been conducted on the response to electro-
acupuncture (EA) treatment applied to angina patients.
Epigenetic modifications of DNA and histones are a pri-
mary mechanism by which gene expression activities
may be modified in response to environmental stimula-
tion. Due to the innate plasticity of DNA methylation of
cytosine bases, environmental cues can induce epigene-
tic shifts in the timing and intensity of gene expressionthat may contribute to a physiological acclimation re-
sponse [20]. Although the vast majority of modifications
remain poorly understood, scientists have seen conside-
rable progress in the understanding of lysine acetylation
and methylation. Whereas lysine acetylation almost al-
ways correlates with chromatin accessibility and transcrip-
tional activity, lysine methylation can have different effects
depending on which residue is modified. Methylation of
histone H3 lysine 4 (H3K4) and H3 lysine 36 is associated
with transcribed chromatin. In contrast, methylation of
H3 lysine 9 (H3K9), H3 lysine 27 (H3K27), and H4 lysine
20 (H4K20) generally correlate with repression [21]. Re-
cent studies show that the acetylation of lysine residues on
histones is a well-established post-translational modifica-
tion, and is a direct regulator of chromatin structure and
function [22]. Two enzyme families, histone acetylase and
histone de-acetylase, control the level of histone acety-
lation and act as critical gene transcriptional activators or
silencers. It is known that post-translational modification
of histone H3K9 is critical for regulation of gene tran-
scription, and includes both acetylation and methylation.
Methylation of histone H3K9 correlates with transcrip-
tional repression, whereas acetylation of the histone H3K9
is associated with transcriptional activation [23]. Our pre-
vious studies on rats have demonstrated that acupuncture
promotes angiogenesis after myocardial ischemia though
regulation of H3K9 acetylation at the VEGF gene [17].
This is the first experimental report showing that acu-
puncture can effectively up-regulate VEGF expression
through H3K9 acetylation modification directly at the
VEGF promoter and hence contribute to angiogenesis in
the rat MI model. A recent study demonstrates that
enhancers play a central role in cell type-specific gene
expression and are marked by H3K4me1/2. Active en-
hancers are further marked by H3K27ac. Using adipoge-
nesis and myogenesis as model systems, Dr. Ge, et al. at
NIH identified that deletion of Mll4 (KMT2D) markedly
decreased H3K4me1/2 and H3K27ac levels on enhancers
and leads to severe defects in cell type-specific gene ex-
pression and cell differentiation [24]. Moreover, others
have found that histone modification-mediated chromatin
remodeling plays an important role in the occurrence of
cardiovascular disease [25]. We now aim to study whether
H3K4me1/2 and H3K27ac can be correlated with the pro-
tective effects of acupuncture at PC6 in human patients.
A few published randomized controlled trials (RCTs)
concerning acupuncture treatment for stable angina pec-
toris claim that convincing evidence for the effectiveness
of acupuncture in treating stable angina pectoris patients
is still inadequate, due to the poor quality of existing
studies. To address these problems and to hopefully pro-
vide a more conclusive answer to these questions, a
team within our research group has designed a protocol
to start a multicenter RCT [26]. In order to study the
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firm the efficacy of electro-acupuncture as a treatment
method for stable angina pectoris using a relatively small
patient population. We will then compare the gene
profiles and histone modifications before and after
electro-acupuncture treatment at Neiguan. This work is
financially supported by the National Basic Research
Program (973 program, No. 2012CB518501) of China.
Methods/Design
Clinical trial
This is a randomized controlled, double-blinded (assessor
and patients) trial containing two acupuncture groups
(Neiguan and Non-acupoint group) and one control
group (Figure 1). Sixty participants will be included from
the following two hospitals: Second Affiliated Hospital of
Nanjing University of Chinese Medicine; and Affiliated
Hospital of Hunan University of Chinese Medicine. These
participants will be randomly assigned to three groups on
a 1:1:1 ratio.
The two acupuncture groups will receive 12 sessions
of electro-acupuncture treatment spanning 4 weeks,
with the frequency of 3 sessions a week. Each session
will last 30 minutes. The follow-up period is 3 months
(5 to 16 weeks after randomization). The control group
will not receive acupuncture treatment in the firstFigure 1 Trial flow chart.4 weeks but will receive routine clinical care in the
hospital. They will be provided 12 sessions of electro-
acupuncture treatment after the 16 weeks as compensa-
tion. Participants will be asked to fill in angina diaries
from one week before randomization to 16 weeks after
randomization. All clinical outcomes are assessed at
baseline and at 4, 8, 12, and 16 weeks after rando-
mization according to the diaries. The laboratory results
are assessed at baseline, 4 weeks, and 16 weeks after
randomization.
Experimental study
Ten ml peripheral blood will be drawn from each par-
ticipant on the day 0, day 30, and at the end of week 16
(Figure 2). All neutrophils are negative selected from the
peripheral blood. After extracting RNA and DNA from
the blood sample, all of the data will be analyzed by high-
throughput sequencer Illumina Hiseq 2000 (Illumina,
USA) in our laboratory. We will analyze the RNA-Seq and
ChIP-Seq data after 30 days of electro-acupuncture treat-
ment. RNA-seq analysis from the experimental patients
will provide acupuncture-related changes in gene expres-
sion and pathway profiles. Meanwhile, RNA-seq data ge-
nerated from the control group will be used to eliminate
background. To detect histone modifications, we perform
ChIP-seq analysis for H3k4me1/2 and H3k27ac.
Figure 2 Experimental study design.
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each patient. All patients are asked to record angina
diaries for one week before randomization (baseline
phase). If they prove eligible for this study, they will be
asked to complete diaries from 0 to 16 weeks after
randomization. Each group will receive basic treatments
including health education and basic drug therapy. We
will recommend, to all patients, lifestyle modifications
that include increasing physical activity, limiting alcohol
consumption, controlling body weight, and quitting smo-
king, etc. The basic medications include Aspirin: 100 mg
quaque die; Metoprolol: 25 mg bis in die; Ramipril: 5 mg
quaque die; and Atorvastatin: 20 mg quaque nocte.
Ethics review and informed consent
This protocol has been approved by the Chinese Clinical
Trail Registry (ChiCTR) on Nov. 9,2012 (Registration
number: ChiCTR-TRC-12002668). It follows the principles
of the Declaration of Helsinki (Version Edinburgh 2000). It
has been reviewed and approved by the Institutional
Review Board of the Second affiliated Hospital Ethic
Committee of Nanjing University of Chinese Medicine
(Approved No.: 2012CB518501) and the First AffiliatedHospital Ethic Committee of Hunan University of Chinese
Medicine (Approved No.: HN-LL-KY-2013-006-01). Be-
fore randomization, all patients will be requested to sign
the written informed consent, during which they will be
given enough time to decide whether they are willing to
participate in this trial. They will be informed of the de-
tails of the study and all benefits and risks of participating
in this trial.
Study population and recruitment
Sample size is calculated based on the primary clinical
measure of effect-frequency of angina attacks, according
to the formula:




Where n is the sample size of trial group/control
group, α is the significance level,1-β is the power of a
test, δ is the mean difference between trial group and
control group. In this study, α = 0.05, β = 0.10, δ is esti-
mated at 4.5 between Neiguan group and control group
based on the primary clinical data, therefore n ≈ 20 is in
each group. Thus, a total of 60 participants were recruited
in outpatient clinics from the two above-mentioned hospi-
tals. The chief physicians of cardiovascular department in
each hospital were invited to attend a discussion on how
to recruit patients. Research assistants from each depart-
ment will help screen participants. To ensure the preci-
sion of results of this study, we developed the following
criteria of eligibility.
Inclusion criteria
Participants will be included in this study if they fulfill
all of the following conditions: 1) Patient was diagnosed
with stable angina according to standards published
by the American College of Cardiology (ACC) and the
American Heart Association (AHA) [27]. 2) Patients ages
between 35 and 80 years old, both male and female;
3) The patient has experienced angina attacks in at least
the last three months, and the attack frequency was equal
to or greater than twice a week in the most recent month;
4) Patient signs the informed consent document. In ad-
dition, to ensure that the results from this study are only
due to the treatments from this study, all participants will
be required not to have received acupuncture therapy for
at least 2 months prior to entering the study.
Exclusion criteria
Patients with any of the following conditions will be ex-
cluded: 1) Pregnant or nursing mothers, including those
who have given birth in the last six months; 2) Patients
with pre-existing severe cardiovascular, digestive, urinary,
respiratory, hematological, nervous, or endocrine system
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3) Patients with psychosis; 4) Patients who are susceptible
to bleeding disorders and/or allergic reactions; 5) Patients
with acute coronary syndrome (including acute myo-
cardial infarction, unstable angina), severe arrhythmia
(including 3rd degree AV block, ventricular tachycardia,
sever supraventricular tachycardia, and frequent premature
contractions, especially premature ventricular contraction),
atrial fibrillation, primary myocardiopathy, or valvular
heart disease; 6) Patients who have experienced unsuc-
cessful treatments for hypertension or diabetes mellitus
(average blood pressure above 140/90 mmHg and HbA1
above 7% in last three months); or 7) Patients participating
in other clinical projects.
Randomization and blinding
Patients will be randomized by an independent statisti-
cian using a computerized, random-number generator
through the block-randomization method of Statistics
Analysis System version 9.2 for sequence generation. Al-
location to the treatment groups uses a stratified block
dynamic randomization method with a permuted block,
which is a computer-based system [26]. Separate rando-
mization files will be created for each of the two recrui-
ting sites. Allocations will be concealed using sealed,
opaque envelopes. After the assessor has screened the
patient for inclusion and the patient has signed the in-
formed consent form, the next envelope in the sequence
will be provided, immediately prior to treatment, to the
certified acupuncturists, who will be conducting acu-
puncture treatment. With this method, the 60 partici-
pants will be randomly assigned to the three groups:
Neiguan (PC6) group, non-acupoint group, and control
group. The acupuncturists and the patients are not in-
volved in the assessments of study results. Blinded as-
sessors are required to conduct outcome assessments,
collect outcome data and angina diaries, and check any
missing data. Laboratory analysts are also blinded to the
clinical evaluation and index. The data are entered by re-
search assistants and analyzed by a statistician. Except
for the acupuncturists, all personnel will not be disclosed
information regarding participant allocation. Professional
statistical assistance is also sought to double-check the
data analysis.
Interventions and comparison
Rationale for acupuncture protocol
The acupuncture protocol was set up upon consulting
acupuncture experts and a variety of acupuncture text-
books. Based on the theory of acupuncture and Traditional
Chinese Medicine (TCM), Neiguan (PC6) (Figure 3A) on
Pericardium Meridian of Hand-jueyin is the classic acu-
point in the treatment of stable angina pectoris. Additio-
nally, to test and verify the clinical efficiency of Neiguan,we have chosen a non-acupoint (Figure 3B) located on the
junction of the deltoid and biceps muscles at the front of
medial upper arm that does not belong to any channel as a
reference point. Therefore, acupuncture groups in our
study are defined as: (1) Neiguan (PC6) on Pericardium
Meridian of Hand-jueyin group; (2) non-acupoint group.
Acupuncture groups
All acupuncture points will be punctured by disposable
filiform needles (ANDY Sterile acupuncture needle,
0.25 × 25 mm). After being needled, the points will be
punctured again using auxiliary needles 2 mm lateral to
the first needle, and to a depth of 2 mm without manual
stimulation. HANS-200E electro-acupuncture apparatus
(HANS, 2-100Hz, made in Jiangsu, China) is used for
electric stimulation at every acupuncture point. Each
acupuncture needle and auxiliary needle at each point is
connected to a stimulus isolation unit with parameters
of 2/15Hz and stimulated for a total of 30 minutes. The
stimulation intensity varies from 0.1 mA to 1.0 mA until
the patients feel comfortable. De qi sensation [28] will
be achieved in the acupuncture groups, through lifting
and thrusting combined with twirling and rotating the
needles. After retaining the needles for 30 min, all nee-
dles are taken out with clean cotton balls to avoid blee-
ding. Every patient will receive treatments three times a
week for a total of 12 treatments, with a 1-day interval
every 2 days of treatment.
Control group
To compare to the acupuncture groups, we randomly
selected 20 cases of patients with stable angina pectoris
as a control group. They will receive basic treatment in-
cluding health education and basic drug therapy, but no
acupuncture treatment in the first 4 weeks. They will
then be provided 12 free sessions of acupuncture treat-
ment after 16 weeks.
Sample preparation and analyses
Neutrophils were selected from peripheral blood
All neutrophils are negative selected by the EasySep™
Human Neutrophil Enrichment Kit (Stemcell) from a
polymorphonuclear cell-rich fraction of peripheral blood.
Unwanted cells are targeted for removal with Tetrameric
Antibody Complexes recognizing CD2, CD3, CD9, CD19,
CD36, CD56, glycophorin A, and dextran-coated magnetic
particles. Labeled cells are separated using an EasySep™
magnet (Stemcell) without the use of columns. Desired
cells are then poured off into a new tube.
RNA-Seq
Total RNAs are extracted by using Trizol reagent
(Invitrogen) from 1 × 107 neutrophils selected from 10 ml
peripheral blood. RNA libraries are prepared according to
A B
Figure 3 Illustration of acupoints. Location of the acupoint Neiguan (Figure 3A). Location of non-acupoin (Figure 3B).
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DNA libraries are applied to the cluster generation and se-
quencing using c-BOT Multiplex re-hybridization plate
and Truseq Sbs kit V3. Sequencing will be performed
using Illumina Hiseq 2000 (Illumina, USA).
ChIP-Seq
ChIP is performed by following a protocol from Myers’
laboratory (http://hudsonalpha.org/myers-lab/protocols)
with modifications. The neutrophils are crosslinked with
1–2% formaldehyde for 10 min at room temperature.
Crosslinking reaction is then stopped by adding 125 mM
glycine. The cells are washed with cold PBS twice. 1 × 107
of these cells are collected in 10 ml Farnham lysis buffer
(5 mM PIPES pH 8.0/85 mM KCl/0.5% NP-40, sup-
plemented with protease inhibitors) and centrifuged at
4,000 g for 5 min at 4°C. The cell pellet is then washed
with 10 ml Farnham lysis buffer, followed by centrifuga-
tion. Resulting nuclear pellet is resuspended in 1 ml TE
buffer (10 mM Tris-Cl pH 7.7/1 mM EDTA, supple-
mented with protease inhibitors) and sonicated for 30 min
(15 s on/off cycle). Lysates are supplemented with de-
tergents to make 1X RIPA buffer (10 mM Tris-Cl pH
7.7/1 mM EDTA/0.1% SDS/0.1% Na-DOC/1% triton
X-100) and centrifuged to remove debris. For each ChIP,
6–8 μg antibodies (H3K4me1, H3K4me2, and H3k27ac)
are prebound to 50 μl Dynabeads Protein A (100.02D; Life
Technologies) overnight at 4°C. On the next day, the
antibody-beads complex is added to chromatin from
2 × 107 cells and further incubated overnight at 4°C. The
beads are then washed twice with RIPA buffer, twice with
RIPA + 0.3 M NaCl, twice with LiCl buffer (50 mMTris-Cl pH 7.5/250 mM LiCl/0.5% NP-40/0.5% Na-DOC),
and twice with PBS. DNA is eluted and reverse cross-
linked in 200 μl elution buffer (1% SDS/0.1 M NaHCO3,
supplemented with 20 μg proteinase K) overnight at 65°C.
The DNA is purified by QIAquick PCR Purification Kit
(QIAGEN) and quantified. DNA and libraries are con-
structed as described (Wei et al. [29]). All ChIP-Seq sam-
ples are sequenced on Illumina HiSeq 2000.
Measurement of Results
Clinical evaluation
The primary measure of effect in our clinical patient is the
frequency of angina during the 4 weeks following ran-
domization, which will be measured at the end of every
4 weeks (on weeks 4, 8, 12 and 16). In addition, we will
document the following seven parameters: visual analogue
scale (VAS), dosage of nitroglycerin tablets, 6-minute walk
test (6-MWT), dynamic ECG observation of the changes
in ST-T, Seattle angina questionnaire (SAQ), the incidence
of cardiovascular episode during the 4 months, self-rating
anxiety scale (SAS), and self-rating depression scale (SDS)
(Table 1). VAS, dosage of nitroglycerin tablets, and SAQ
will be measured one week prior to randomization and at
4, 8, 12 and 16 weeks after randomization. Dynamic ECG
observation of the changes in ST-T will be measured be-
fore randomization and 4 weeks after randomization. The
incidence of cardiovascular episodes during the 4 months
will be measured at the end of the 16 weeks in patients
who have received the 12 sessions of electro-acupuncture
treatment.
All patients will be asked to record angina diaries one
week before randomization (baseline phase) and 4, 8 and
Table 1 Trial process chart
Baseline Treatment phase Follow-up phase
−1 week 0 day 4 weeks 8 weeks 12 weeks 16 weeks
Patients
Inclusion and exclusion *
Allocate informed consent *





PC6 group (n = 20)
12 sessions of acupuncture
Non-acupoint point group (n = 20)
Comparison
Control group (n = 20)
Outcomes
Angina attacks in four weeks * * * *
VAS * * * * *
Dosage of nitroglycerin * * * * *
6-MWT * *
SAQ * * *
SAS * * *
SDS * * *
The incidence of cardiovascular episode during the 4 months *
Dynamic ECG Observation of the changes of ST-T * *
Clinic evaluation
Safety of electro-acupuncture * *
Adverse events * * * *
Patient’s compliance *
Reasons of drop-out withdrawals *
Laboratory evaluation
Blood collection * * *
RNA & DNA extraction * * *
RNA-Seq & ChIP-Seq data analysis * *
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ceive routine blood, urine, and stool tests, an electrocar-
diogram (ECG), 24-hour dynamic electrocardiography
(DCG), echocardiographic tissue Doppler imaging (TDI),
liver function tests (ALT, AST), and kidney function
tests (BUN, Scr) before randomization, in order to ex-
clude patients who have serious heart, liver, kidney, or
other severe diseases. Routine tests will be run twice be-
fore randomization and after the completion of electro-
acupuncture treatment.
To guarantee the quality of the study, all acupunctu-
rists are required to attend special training classes. Thepurpose of these training classes is for acupuncturists to
understand all the details of this study. The special trai-
ning classes focus on theoretical and practical lessons.
They will be trained to use the central randomization
method, to fill in the case report form, to find the cor-
rect points, to manipulate the needles, and to choose the
correct electro-acupuncture apparatus. Acupuncturists
are qualified to participate in this study only upon com-
pletion of all training classes, along with passing the
assigned training examination. Additionally, to ensure
the quality of this trial, a clinical proctor will check the
processes of the trial and document the details at the
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the proctor will further survey the reasons for the pa-
tient’s leaving, as well as record the last treatment for
that patient as soon as possible.
Laboratory evaluation
Computational analysis for RNA-Seq data
After sequencing with HiSeq2000 (Illumina), raw fastq
files are extracted from Illumina BCL using the Illumina
CASAVA program. The single-end reads of biological
triplicates obtained from each sample are to the rat refe-
rence genome (UCSC rn4 assembly) using the TopHat
program [30,31]. The Cufflinks program will be used to
assemble individual transcripts from RNA-Seq reads that
have been aligned to the genome and to qualify the ex-
pression level of each transcript. Differential transcripts
expression analysis is performed with the Cuffdiff pro-
gram. The gene’s functional annotation and pathway are
analyzed using the DAVID Bioinformatics Resources [32].
Computational analysis for ChIP-Seq data
The sequence reads are of 50 bp in length and aligned
to reference genome assembly NCBI. The output of the
Illumina Analysis Pipeline is then converted to browser
extensible data (BED) files detailing the genomic coordi-
nates of each mapped read. To visualize the data on the
UCSC genome browser (Karolchik et al. [33]), reads are
collected and converted to wiggle (WIG) format using
an in-house script.
Follow-up
Follow-up tests will be conducted 8, 12 and 16 weeks after
randomization. The follow-up assessment is designed to
evaluate the long-term effects of stable angina pectoris.
Adverse events
Any adverse events, such as bleeding, hematoma, fainting,
serious pain, and local infection, during treatment will be
recorded during treatment and in the follow-up period by
the acupuncturist. In case of abnormal reactions, the date
of appearance and disappearance, the degree of reaction,
parameters selected for electro-acupuncture treatment,
names of OTC (over the counter) drugs taken outside of
the treatment, whether the abnormal reactions were
treated, and any other related information will be recorded
in detail. Serious adverse events should be reported to the
principal investigator immediately. Any medical condi-
tions or diseases present prior to the start of the treatment
will be considered abnormal reactions only if they worsen
after the start of the treatment. Abnormal test values or
results will be considered abnormal reactions only if they
cause clinical symptoms, are considered clinically signifi-
cant, or require treatment.Clinic statistical analysis
The results of the intention-to-treat (ITT) analysis will
be used to assess the validity of the study as a whole.
The per-protocol (PP) analysis results will be used as a
reference. The ITT analysis will be used as the main
safety assessment technique.
Continuous data will be represented by the average,
standard deviation, minimum value, and maximum
value, whereas categorical data will be represented by a
frequency table. For comparison of the results among
the groups, the analysis of variance (ANOVA) test will
be used when the data are normally distributed; the
Kruskal-Wallis test will be used otherwise. In addition, a
chi-square test will be performed for categorical data.
After 4 weeks, different outcomes will be summarized
for each group using descriptive statistics, including the
median, average, standard deviation, and interquartile
range. The differences in angina attacks following the
treatment for each group will be analyzed using a paired
t-test or a Wilcoxon signed rank test, and a 95% confi-
dence interval will be presented. To assess the difference
in the tendency for each visit, a repeated analysis of va-
riance will be performed. A significance level of 5% will
be used in all analyses.
VAS, dosage of nitroglycerin tablets, 6-MWT, dynamic
ECG observation of the changes of ST-T, SAQ, the inci-
dence of cardiovascular episode during the 4 months,
self-rating anxiety scale (SAS), and self-rating depression
scale (SDS) will be analyzed using the same techniques
used to analyze the validity of the assessment variable.
To determine whether there are differences in the dis-
tribution of symptomatic changes among the groups,
analysis will be performed on each item using the chi-
squared test.
All adverse reactions manifested will be listed with de-
tailed explanations. The frequency of abnormal reactions
that are correlated with the treatment and abnormal reac-
tions that do not have such correlations will be recorded.
A Fisher’s exact test will be performed to determine
whether there are any differences among the groups with
respect to the incidence of abnormal reactions as reported
by the subjects. Furthermore, technical analysis will be
performed to identify differences in the degree of severity
and in the type of abnormal reactions among the groups.
There is one acupuncturist at each site to do all in-
terventions, which can potentially introduce a clustering
effect in this trial. Therefore, we have calculated the
intracluster correlation coefficient from the results of
this trial and have reported the coefficient [34].
Discussion
Angina pectoris predisposes a patient to other cardio-
vascular complications, and affects the patient’s health
and quality of life. This study is expected to provide
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has protective effects against angina, and that many
functional genes and pathways contribute to such effects.
Moreover, histone modifications are expected to mediate
the changes of gene expressions caused by electro-
acupuncture treatment.
Grouping and acupoint selection
There are three acupuncture groups in this trial, inclu-
ding a Neiguan (PC6) group, a non-acupoint group, and
a control group. Some reports state that acupuncture on
Neiguan may increase the usage of nitroglycerin, just as
we have mentioned previously [14]. Therefore, to ensure
the quality of research, we asked all participants to use
nitroglycerin. In order to avoid interference caused by
nitroglycerin’s therapeutic effect, we set up this control
group. Our pilot experiment has shown that neither the
clinical efficacy nor the molecular changes resulted from
acupuncture treatment at Neiguan has been affected by
the basic use of drugs. Compared with the control
group, we can not only determine the effectiveness of
electro-acupuncture on the patients with stable angina
pectoris, but also compare the profiles of gene expres-
sion and histone modifications. In order to meet the re-
quirements of ethics, the patients in control group will
be provided 12 free sessions of electro-acupuncture
treatment after 16 weeks. Therefore, we are also able to
detect the differences in histone modifications before
and after electro-acupuncture treatment at Neiguan for
these patients.
The functions of non-acupoint have been reported as
controversial by some studies that have shown no diffe-
rence between acupoint and non-acupoint stimulation
[35-37]. To clarify the specificity of acupoint PC6, we set
up the non-acupoint group to be a reference point that
does not belong to any meridian. We have strategically
chosen a non-acupoint as a reference point based on
two principles. The first is based on Traditional Chinese
Medicine theories and literatures [24]. In most Chinese
literature, the preferred non-acupoints is located closely
beside therapeutic acupoints and half way between two
lines or acupoints [38,39]. The second is based on our
previous studies using animal models (unpublished). We
have chosen a standard position that does not result in
the same effects as the acupoint PC6 when stimulated
and has no documented adverse events.
Target tissue/cell for laboratory study
By using high-throughput sequencing, we can investigate
genome-wide gene expressions and histone modifica-
tions before and after electro-acupuncture treatment,
and then analyze the correlations between acupuncture
effects and histone modifications. As a clinical trial, it is
not possible to study cardiac tissues of the patients, thus,blood samples are our specimen of choice, and neutro-
phils are the target cells. Neutrophils, as a hallmark of
acute inflammation, has been proven, via autopsy spe-
cimens of culprit lesions from acute MI patients, to be
vital to acute plaque rupture, demonstrating higher con-
centrations of activated neutrophils than in those with-
out acute coronary syndrome (ACS) [40]. More recently,
the neutrophil/lymphocyte ratio (NLR) has been also
proposed as a useful biomarker for predicting cardiovas-
cular risk [41]. Therefore, we have chosen neutrophil as
target cells in this study. As a possible result, many path-
ways found to be effectively activated or repressed by
electro-acupuncture treatment might be related to im-
mune response or inflammation.Epigenetic marks
Our previous study has demonstrated that electro-
acupuncture can promote angiogenesis after myocardial
ischemia through H3K9 acetylation regulation at VEGF
gene in rat heart tissue [17]. We now focus on two epi-
genetic marks, H3K4me1/2 and H3K27ac and analyze
their genome-wide regulation profiles in this study. Their
increased binding to genes in response to acupuncture
intervention could indicate an activated chromatin remo-
deling, and hence a positive regulation for functional gene
expressions. Because of budget constraints, we were unable
to analyze other epigenetic marks reported to be important
for gene regulation, such as H3K4me3, H3K27me3 and
H3K9ac.
In conclusion, the results of this study are expected to
confirm the effectiveness of electro-acupuncture in the
management of stable angina pectoris, and to determine
the key role that histone modifications play in gene
regulation under acupuncture in stable angina. Our
study will provide the first set of gene expression profile
for stable angina pectoris and their changes induced by
electro-acupuncture. Through in-depth study of histone
modifications, we may uncover some molecular evidences
of the effects of acupuncture, which can prove useful for
basic and clinical researchers, as well as for clinical
practitioners.
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